Navigation Links
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:10/20/2009

SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the BIOCOM Life Science Investor Conference on Monday, October 26, 2009 at 5:00 p.m. PDT (8:00 p.m. EDT). The conference is being held at the Hyatt Regency La Jolla Hotel in San Diego. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.

Dr. Worland will also present a Company overview at the 8th Annual BIO Investor Forum on Wednesday, October 28, 2009 at 10:00 a.m. PDT (1:00 p.m. EDT). The conference is being held at the Palace Hotel in San Francisco.

Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software. A replay of the presentation at the BIOCOM Life Science Investor Conference will be available approximately one hour after the live webcast concludes and will be available through November 9, 2009. A replay of the presentation at the 8th Annual BIO Investor Forum will be available approximately one hour after the live webcast concludes and will be available through November 11, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is deve
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ANTONIO , Jan. 15, 2014 Most osteoporosis ... according to a recent online survey* sponsored by Mission ... among the National Osteoporosis Foundation online support community, revealed ... take medication that comes in a form other than ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... Pharmaceuticals, Inc.  (Nasdaq: PCRX ) today announced ... from 381 U.S. hospitals who underwent common hospital-based surgical ... data demonstrate that opioid-related adverse events (ORAEs) are associated ... and more than a day increase in length of ...
... 2, 2011  WestPark Capital, Inc. announced the completion of ... total of 2,817,988 shares of common stock and warrants ... were sold, generating gross proceeds of $2,592,549 in the ... new applications for IsoRay,s Cesium-131 technology to treat lung, ...
Cached Medicine Technology:New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 2New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 3New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 4WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering 2
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... donors was safe and effective in treating patients ... difficile , according to a new pilot study ... available online. Known as fecal microbiota transplantation, the ... colonoscope or a nasogastric tube. The findings suggest ... readily available to patients. , A growing concern, ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... Work in primates points to possible weapon against human ... News) -- Researchers have successfully tested several Ebola vaccines ... first human vaccine for one of the world,s deadliest ... cannot be overlooked. We are seeing more and more ...
... has established that patients with a high blood pressure in ... of pumping blood against this pressure. Further, the right ventricle ... is the first Mosaic laureate to gain his doctorate. ... into the cause of high blood pressure in the lungs ...
... in French . , Montreal, March 31, 2008 ... a novel gene responsible for a significant fraction of ALS ... as Lou Gehrigs disease, an incurable neuromuscular disorder that affects ... to five years. , Published in the current online edition ...
... the manufacturer,of the SurgiLance safety lancet, has made ... Foundation (JDRF) to support ongoing research,efforts. MediPurpose made ... of its,500 millionth safety lancet to St. Louis-based ... improving the quality of life for those,living with ...
... 31 ReBuilder,Medical Technologies, Inc. (Pink Sheets: RBRM), ... diabetic peripheral neuropathy, Molluscum,Contagiosum, and MRSA; today reported ... when they sold over $25,000 in products., ... have not been affected thus far by the ...
... Highlights Key Issues and Offers Suggestions on ... Improvements for Hospital Administrators, NEW YORK, March ... delivery of a baby is a significant decision. But,there are ... departments,around the country that must function properly in order to ...
Cached Medicine News:Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Researchers identify a gene responsible for Lou Gehrig's disease 2Health News:MediPurpose Supports Diabetes Research Effort 2Health News:ReBuilder Medical Technologies, Inc. Announces Best Sales Day in 5 Years 2Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4
... A wide range of miniTHERM incubators ... the appropriate application solution for their specific ... 18 liters, are compact and extremely space ... typical microwave oven. It is possible to ...
... A wide range of miniTHERM incubators is ... appropriate application solution for their specific requirements. ... liters, are compact and extremely space saving. ... microwave oven. It is possible to stack ...
... resistance of stainless steel with the ... offers an electro-polished copper-alloy-stainless interior that ... sterile environment promotes the integrity of ... safety of laboratory staff. This exclusive ...
IR Autoflow Dual Chamber Over-Under Water-Jacketed CO 2 Inc....
Medicine Products: